CNT-DM-03

CNT-DM-03 is a peptide-based synthetic molecule being developed by Centurion (Centurion Pharma) for the treatment of alimentary and metabolism-related disorders, specifically diabetes mellitus. It is formulated for administration via a pre-filled syringe (PFS). The drug is part of Centurion's "DM" series of diabetes treatments, which also includes CNT-DM-01 and CNT-DM-02 (both pen formulations). As a peptide-based synthetic molecule in the metabolic space, it likely functions as a glucagon-like peptide-1 (GLP-1) receptor agonist or a similar metabolic hormone analog, although its specific molecular target has not been publicly disclosed by the sponsor.